Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- Cleveland Clinic lists potential conflicts of interest online
- HHS: 60 percent of DME companies banned by Medicare may keep billing
Poll
Featured Jobs
-
Tennessee Occupational Medicine
StaffPointe, LLC - near Nashville , TN -
Illinois Cardiac Cath Lab Nurse
StaffPointe, LLC - Bloomington , IL -
Texas Dir. of Med/Surg
StaffPointe, LLC - east , TX -
Washington Nurse Practitioner
StaffPointe, LLC - Tacoma/Olympia , WA -
Wisconsin-Family Medicine
Ohrmund Employment Group - Cedarburg, WI
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
FDA report pains Boston Scientific
June 22, 2006 — 8:01pm ET
An internal FDA estimate of the dangers posed by a Boston Scientific pacemaker suggests that they may be far higher than earlier estimates had suggested. In the report, agency experts argue that the odds of the Contak Renewal short circuiting may be ten times higher than than its maker previously admitted. Boston Scientific acquired the pacemaker when it bought Guidant in a $27-billion deal. The news comes a day after The Wall Street Journal published a front-page piece suggesting that leading cardiac centers may be moving away from using the company's drug-coated stents.
- see this article from Bloomberg News
Related Stories
- The FDA warns Boston Scientific
- Patients face defibrillator recalls
- Boston Scientific announces recall, shares drop
- Guidant Merger Signifies Technological Shift
- FDA investigates Taxus stent
- J&J wants new terms for Guidant deal
- Medical device monitoring network runs short on funding
- ALSO NOTED: PA schedules hearings on Independence/Highmark merger; Medical college group urges caution with pharma tech freebie
- Decision makes it harder to sue device makers
- Researcher settles price disclosure case with Guidant
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





